Date 2019-12-27 Location TICC, Taipei Presentation Download Download Chinese Version Download English Version Note N/ARead More

Published Date:2019-12-16 Original Link:https://www.onenessbio.com/en/news_detail101_1.htm Contact Us繁簡ENRead More

Published Date:2019-12-13 Original Link:https://www.onenessbio.com/en/news_detail102_1.htm Contact Us繁簡ENRead More

  BfArM, the German Federal Institute for Drugs and Medical Devices has confirmed acceptance of the IND application of Oneness Biotech for Phase 3 trial of diabetic foot ulcer new drug, ON101 (protocol#ON101CLCT04).Read More

  The merger between Oneness Biotech and Fountain Biopharma makes the pipeline and resources integrated. The pipeline will include a late-stage drug to be launched in global market as well as new drugs in earlier clinical stage in immunology. This merger will strengthen the R&D capability in favor of global collaboration and competition.Read More